Grants and Contributions:
Title:
PK and tolerability xenograft testing for lead oncology compound
Agreement Number:
919111
Agreement Value:
$44,327.00
Agreement Date:
Jan 7, 2019 - Jun 21, 2019
Description:
Tieös Pharmaceuticals is a pre-clinical stage biotech company, with the goal of creating novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells.
With the use of advanced AI-based computational biology and 3D in-silico models, we have developed lead polypharmocological compounds which will each target multiple metabolic pathways simultaneously; creating synergies and reducing toxicity. Through a proprietary weighting of cancer specific metabolic pathways, we have now synthesized our five lead compounds and are conducting proof-of-concept in-vitro testing.
At Tieös, we have designed compounds which target onco-specific enzymes simultaneously – our goal is to starve cancer cells of their energy.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Moffat, New Brunswick, CA E1A 6N9
Reference Number:
172-2018-2019-Q4-919111
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
756525093
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amendment value is 28,971 dollars.
Amendment Date
Apr 2, 2019
Recipient's Legal Name:
Tieos Pharmaceuticals Inc.
Federal Riding Name:
Moncton--Riverview--Dieppe
Federal Riding Number:
13007
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: